JCB logo
MBL International Tel: 800.200.5459 CLICK HERE
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 602K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by South, S. T.
Right arrow Articles by Gould, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by South, S. T.
Right arrow Articles by Gould, S. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

© The Rockefeller University Press, 0021-9525/2000//1345 $5.00
The Journal of Cell Biology, Volume 149, Number 7, , 2000 1345-1360


Original Article

Inhibitors of Copi and Copii Do Not Block PEX3-Mediated Peroxisome Synthesis



Sarah T. Southa, Katherine A. Sackstedera, Xiaoling Lia, Yifei Liua, and Stephen J. Goulda

a Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205
Department of Biological Chemistry, 725 North Wolfe Street, Baltimore, MD 21205.(410) 955-0215(410) 955-3085

sgould{at}jhmi.edu

In humans, defects in peroxisome biogenesis are the cause of lethal diseases typified by Zellweger syndrome. Here, we show that inactivating mutations in human PEX3 cause Zellweger syndrome, abrogate peroxisome membrane synthesis, and result in reduced abundance of peroxisomal membrane proteins (PMPs) and/or mislocalization of PMPs to the mitochondria. Previous studies have suggested that PEX3 may traffic through the ER en route to the peroxisome, that the COPI inhibitor, brefeldin A, leads to accumulation of PEX3 in the ER, and that PEX3 overexpression alters the morphology of the ER. However, we were unable to detect PEX3 in the ER at early times after expression. Furthermore, we find that inhibition of COPI function by brefeldin A has no effect on trafficking of PEX3 to peroxisomes and does not inhibit PEX3-mediated peroxisome biogenesis. We also find that inhibition of COPII-dependent membrane traffic by a dominant negative SAR1 mutant fails to block PEX3 transport to peroxisomes and PEX3-mediated peroxisome synthesis. Based on these results, we propose that PEX3 targeting to peroxisomes and PEX3-mediated peroxisome membrane synthesis may occur independently of COPI- and COPII-dependent membrane traffic.

Key Words: Zellweger syndrome • membrane biogenesis • protein import • vesicle traffic • peroxisome biogenesis disorders



© 2000 The Rockefeller University Press

Abbreviations used in this paper: BFA, brefeldin A; GALT, β-1,4-galactosyltransferase; ORF, open reading frame; PBD, peroxisome biogenesis disorder; PMP, peroxisomal membrane protein; RT, reverse transcriptase; WT, wild-type.



Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents